Figure 3.

Single-CEL modifications decrease MTT reduction independent of a change in basal levels of necrosis and apoptosis. All experiments performed after 24 h of 10 μm peptide treatment in RA-differentiated SH-SY5Y human neuroblastoma cells. A, Aβ1–42, Aβ-CEL16, and Aβ-CEL28 inhibit MTT reduction, however, Aβ-CEL16&28 does not inhibit MTT reduction. MTT reduction was measured after 24 h of 10 μm peptide treatment. Results are presented as mean ± S.E. (n = 3–4). B and C, no significant difference in LDH release and caspase 3/7 activity was observed for all peptide treatments relative to the vehicle (Veh). Results are presented as mean ± S.E. (n = 4). *, p < 0.05 relative to the vehicle. p value for all experiments were calculated using Bonferroni's post hoc test in a one-way ANOVA from randomized complete block design.